Richard S Finn

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Targeting Src in breast cancer
    R S Finn
    Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    Ann Oncol 19:1379-86. 2008
  2. pmc Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
    Richard S Finn
    Geffen School of Medicine at University of California, Los Angeles, CA, USA
    J Clin Oncol 27:3908-15. 2009
  3. pmc Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    R Y Tsang
    Department of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
    Br J Cancer 106:6-13. 2012
  4. doi request reprint Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
    Richard S Finn
    University of California Los Angeles, Los Angeles, CA, United States Electronic address
    J Hepatol 59:1271-7. 2013
  5. ncbi request reprint Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Hepatology 57:1838-46. 2013
  6. doi request reprint Emerging targeted strategies in advanced hepatocellular carcinoma
    Richard S Finn
    Division of Hematology Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    Semin Liver Dis 33:S11-9. 2013
  7. doi request reprint Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma
    Richard S Finn
    Geffen School of Medicine, UCLA, Los Angeles, California, USA
    Clin Cancer Res 18:2090-8. 2012
  8. ncbi request reprint Advanced HCC: emerging molecular therapies
    R S Finn
    Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, USA
    Minerva Gastroenterol Dietol 58:25-34. 2012
  9. pmc PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
    Breast Cancer Res 11:R77. 2009
  10. doi request reprint Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
    Richard S Finn
    Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
    J Clin Oncol 27:5552-8. 2009

Collaborators

Detail Information

Publications45

  1. ncbi request reprint Targeting Src in breast cancer
    R S Finn
    Department of Medicine, Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
    Ann Oncol 19:1379-86. 2008
    ..Importantly, recent preclinical data support a role for this class of inhibitors in basal-type/triple-negative breast cancer, which represents a group of patients with limited effective treatment options...
  2. pmc Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in
    Richard S Finn
    Geffen School of Medicine at University of California, Los Angeles, CA, USA
    J Clin Oncol 27:3908-15. 2009
    ..Published data support interactions between steroid hormone and peptide growth factor signaling. We hypothesized that molecular subgroups may exist within EGF30001 that would benefit from lapatinib...
  3. pmc Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    R Y Tsang
    Department of Oncology, Division of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
    Br J Cancer 106:6-13. 2012
    ..In this review, early-phase and emerging trial data surrounding the use of these promising agents in HER2-positive MBC will be discussed...
  4. doi request reprint Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
    Richard S Finn
    University of California Los Angeles, Los Angeles, CA, United States Electronic address
    J Hepatol 59:1271-7. 2013
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) of everolimus given with sorafenib 400mg twice daily in patients with advanced HCC of Child-Pugh class A liver function who were naive to systemic therapy...
  5. ncbi request reprint Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Hepatology 57:1838-46. 2013
    ..The results demonstrate that sensitivity to dasatinib was associated with a progenitor subtype. Dasatinib was effective at inducing cell cycle arrest and apoptosis in "progenitor-like" cell lines but not in resistant lines...
  6. doi request reprint Emerging targeted strategies in advanced hepatocellular carcinoma
    Richard S Finn
    Division of Hematology Oncology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    Semin Liver Dis 33:S11-9. 2013
    ..Therapies targeting other molecular pathways in HCC are in early development; future research will focus on discovering additional targets for therapy and identifying biomarkers that predict the success of current therapies...
  7. doi request reprint Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma
    Richard S Finn
    Geffen School of Medicine, UCLA, Los Angeles, California, USA
    Clin Cancer Res 18:2090-8. 2012
    ..This phase II open-label study assessed brivanib as second-line therapy in patients with advanced HCC who had failed prior antiangiogenic treatment...
  8. ncbi request reprint Advanced HCC: emerging molecular therapies
    R S Finn
    Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, USA
    Minerva Gastroenterol Dietol 58:25-34. 2012
    ..In this review, we will focus on those agents currently in Phase III studies for front-line, second-line and other indications...
  9. pmc PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
    Breast Cancer Res 11:R77. 2009
    ..To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines...
  10. doi request reprint Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
    Richard S Finn
    Geffen School of Medicine at UCLA, Norris Cancer Center, University of Southern California, Los Angeles, CA 90095, USA
    J Clin Oncol 27:5552-8. 2009
    ..We examined the prognostic and predictive role of HER2 ECD in a randomized trial of paclitaxel with placebo or lapatinib in women with HER2-negative or -unknown breast cancer...
  11. ncbi request reprint Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Richard S Finn
    Division of Hematology Oncology, Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 16:390-7. 2010
    ..Here, we review these data in the context of rational drug development in HCC in the front-line setting and in previously treated patients...
  12. ncbi request reprint Monoclonal antibody therapy for breast cancer: herceptin
    Richard S Finn
    Geffen School of Medicine, UCLA, Department of Medicine, Los Angeles, CA 90095, USA
    Cancer Chemother Biol Response Modif 21:223-33. 2003
  13. doi request reprint Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, 11 934 Factor Building, Los Angeles, CA 90095, USA
    Expert Rev Anticancer Ther 9:503-9. 2009
    ..Here, we will review the data supporting the targeting of the VEGF axis in HCC and the preclinical and early clinical development of bevacizumab...
  14. doi request reprint Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Liver Int 29:284-90. 2009
    ..Bevacizumab, a humanized anti-VEGF monoclonal antibody, is currently being evaluated in the treatment of HCC. In addition, other novel anti-angiogenesis agents are being developed in HCC...
  15. ncbi request reprint Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro
    Richard S Finn
    Department of Medicine, Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA 90095, USA
    Breast Cancer Res Treat 105:319-26. 2007
    ..e. hormonal manipulation or trastuzumab)...
  16. doi request reprint Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study
    Richard S Finn
    Department of Medicine, Division of Hematology, Oncology, Geffen School of Medicine, UCLA Medical Center, Los Angeles, California 90095, USA
    Clin Cancer Res 17:6905-13. 2011
    ..This phase 2 trial assessed efficacy and safety of single-agent dasatinib in patients with advanced triple-negative breast cancer (TNBC)...
  17. doi request reprint Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Mol Cancer Ther 12:632-42. 2013
    ..Dovitinib may have antitumor activity in endometrial cancer beyond FGFR2-mutated cases and may permit greater flexibility in patient selection...
  18. pmc Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines
    Edward B Garon
    1Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer Ther 9:1985-94. 2010
    ..In total, these results suggest that clinical trials of selumetinib in breast cancer and NSCLC might select patients whose tumors harbor raf and ras mutations, respectively...
  19. ncbi request reprint Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib
    Ondrej Kalous
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Cancer Ther 11:1978-87. 2012
    ....
  20. doi request reprint Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer
    Zev A Wainberg
    University of California Geffen School of Medicine, Department of Medicine, Division of Hematology Oncology, Santa Monica, CA 90404, USA
    Mol Cancer Ther 12:509-19. 2013
    ..The combination of HSP90 inhibition and direct HER2 blockade represents a novel approach to the treatment of HER2-amplified cancers and clinical trials based on the above data are ongoing...
  21. pmc Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer
    Edward B Garon
    Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90404, USA
    J Thorac Oncol 8:270-8. 2013
    ..To explore cross-communication between ER and EGFR, we have correlated ER pathway gene and protein expression profiles and examined effects of antiestrogens with or without EGFR inhibitors in preclinical models of human NSCLC...
  22. ncbi request reprint HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer
    Michael F Press
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90033 0800, USA
    Clin Cancer Res 14:7861-70. 2008
    ..Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy...
  23. pmc The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth
    Edward B Garon
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Mol Cancer Ther 12:890-900. 2013
    ..These data will help inform the evaluation of correlative data from a recently completed phase II NSCLC trial and a planned phase IB trial of NVP-AUY922 in combination with pemetrexed in NSCLCs...
  24. doi request reprint A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach
    Carolyn D Britten
    Department of Medicine, University of California, Los Angeles, CA, USA
    Clin Breast Cancer 9:16-22. 2009
    ..This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmacokinetics, and response rate of erlotinib plus trastuzumab in metastatic HER2+ breast cancer...
  25. doi request reprint Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo
    Zev A Wainberg
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, California 90404, USA
    Clin Cancer Res 16:1509-19. 2010
    ....
  26. ncbi request reprint AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53
    Ondrej Kalous
    Division of Hematology Oncology, Department of Medicine, Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11 934 Factor Bldg, Los Angeles, CA, 90095, USA
    Breast Cancer Res Treat 141:397-408. 2013
    ..We have found that AMG 900 is highly active in breast cancer cell lines and that TP53 loss of function mutations as well as low baseline expression of p21 protein predict strongly for increased sensitivity to this compound in vitro. ..
  27. ncbi request reprint Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy
    Sammy Saab
    Departments of Medicine, The University of California at Los Angeles, Los Angeles, CA, USA
    Exp Clin Transplant 8:307-13. 2010
    ..Liver transplant can be a definitive treatment for hepatocellular carcinoma. However, recurrence limits long-term survival. Sorafenib is the first agent to improve survival for patients with advanced hepatocellular carcinoma...
  28. pmc Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study
    Carolyn D Britten
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Santa Monica, CA 90404 2429, USA
    BMC Cancer 12:16. 2012
    ..This pilot study examined whether intravenous (IV) bevacizumab, a monoclonal antibody against VEGF, could inhibit neovessel formation after TACE...
  29. pmc Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab
    Ferdows Ather
    Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 8:e56112. 2013
    ..Neither pAKT nor tAKT was associated with sensitivity...
  30. doi request reprint Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
    Gottfried E Konecny
    Division of Hematology Oncology, Department of Biomathematics and Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 17:1591-602. 2011
    ..PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer...
  31. ncbi request reprint A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
    Andrew X Zhu
    Authors Affiliations Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts David Geffen School of Medicine, University of California, Los Angeles, California Northwestern University Feinberg School of Medicine, Chicago Illinois East Jefferson General Hospital, Metairie, Louisiana Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Bridgewater, New Jersey Eli Lilly and Company, Indianapolis, Indiana and Lahey Hospital and Medical Center, Tufts University School of Medicine, Burlington, Massachusetts
    Clin Cancer Res 19:6614-23. 2013
    ..To assess the efficacy and safety of the anti-VEGF receptor-2 (VEGFR-2) antibody ramucirumab as first-line therapy in patients with advanced hepatocellular carcinoma and explore potential circulating biomarkers...
  32. ncbi request reprint Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma
    Robert G Gish
    Section of Hepatology, UC San Diego Health Systems, San Diego, California, USA
    Clin Adv Hematol Oncol 11:1-22; quiz 2 p following p22. 2013
    ..Sorafenib has demonstrated a significant survival advantage in these patients. Numerous studies have evaluated other novel targeted therapies in this setting, but none have shown superiority to sorafenib. ..
  33. pmc SRC: a century of science brought to the clinic
    Alexey Aleshin
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
    Neoplasia 12:599-607. 2010
    ..The status of SRC inhibitors, including dasatinib, saracatinib, and bosutinib, which are in phase 1, 2, and 3 trials, is highlighted...
  34. pmc Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
    Marlena S Fejzo
    Division of Hematology Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Int J Mol Sci 14:3094-109. 2013
    ..Taken together, the results indicate that amplified ADRM1 is involved in cell proliferation, migration and survival in ovarian cancer cells, supporting a role as an oncogene and novel therapeutic target for ovarian cancer...
  35. ncbi request reprint EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells
    Joshua A Bryant
    Department of Neurology David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California90095, USA
    Cancer Biol Ther 3:1243-9. 2004
    ..Distinct intra- and intercellular Ca2+ signaling pathways may be mechanisms by which EGF modulates the growth and migration of tumor cells...
  36. doi request reprint Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma
    Johnny C Hong
    Dumont UCLA Liver Cancer and Transplant Centers, Pfleger Liver Institute, Department of Surgery, David Geffen School of Medicine at University of California, Los Angeles, CA 90095 7054, USA
    J Am Coll Surg 212:514-20; discussion 520-1. 2011
    ..The present study was undertaken to define a prognostic scoring system for risk stratification of patients with intrahepatic and hilar CCA who might benefit from OLT and to allow expansion of current OLT criteria...
  37. ncbi request reprint Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
    Neil A O'Brien
    Authors Affiliations Division of Hematology Oncology, Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, California
    Clin Cancer Res 20:3507-20. 2014
    ..Altered PI3K/mTOR signaling is implicated in the pathogenesis of a number of breast cancers, including those resistant to hormonal and HER2-targeted therapies...
  38. pmc Current approaches and future directions in the treatment of HER2-positive breast cancer
    Sara A Hurvitz
    University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cancer Treat Rev 39:219-29. 2013
    ..Here we will review the current scientific rationale for these agents and how combinations of these agents may yield additive or synergistic effects and lead to improved outcomes for patients with HER2-amplified breast cancer...
  39. doi request reprint Brivanib: a review of development
    Tina Chou
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Future Oncol 8:1083-90. 2012
    ..In this review, we will discuss the preclinical science driving brivanib's development and the clinical data generated to date...
  40. doi request reprint What's positive about 'triple-negative' breast cancer?
    Sara A Hurvitz
    Geffen School of Medicine at UCLA, CA 90095, USA
    Future Oncol 5:1015-25. 2009
    ..Here, we will review the current molecular understanding of 'triple-negative' breast cancer and highlight current clinical research in this challenging group of patients...
  41. pmc Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
    G E Konecny
    Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90404 2429, USA
    Br J Cancer 101:1699-708. 2009
    ....
  42. ncbi request reprint A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors
    D Ross Camidge
    Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado 80045, USA
    Anticancer Drugs 19:77-84. 2008
    ..i.d.) on days 1-14 every 21 days. Further disease-directed studies are warranted, such as in malignancies in the treatment of which both capecitabine and inhibitors of angiogenesis have previously been benchmarked as being effective...
  43. doi request reprint Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
    Richard S Finn
    Authors Affiliations Geffen School of Medicine at UCLA Norris Cancer Center, University of Southern California, Los Angeles, California GlaxoSmithKline, Collegeville, Pennsylvania GlaxoSmithKline, Durham, North Carolina and Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 20:736-43. 2014
    ..The hypothesis that low hormone receptor status is associated with benefit in this HER2-negative cohort was tested...
  44. pmc Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling
    Jennifer Chun
    Bioengineering Interdepartmental Program, Los Angeles, California, USA
    Analyst 137:5495-8. 2012
    ....
  45. ncbi request reprint Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor
    Jitesh P Jani
    Department of Cancer Discovery, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Cancer Res 67:9887-93. 2007
    ..P.o. administration (q.d. or b.i.d.) of CP-724,714 inhibits the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects...